CA
LGND icon

Claris Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Claris Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-32
Closed -$3.2K – 662
2024
Q3 		$3.2K Buy
+32
New +$3.22K ﹤0.01% 304

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Claris Advisors's LGND Position: Q4 2024 in Review

Claris Advisors sold out of Ligand Pharmaceuticals (LGND) in Q4 2024, closing a stake of 32 shares — an estimated $3.2K sold.

Claris Advisors first reported a position in LGND in Q3 2024 and held it in 1 quarter. The position peaked at $3.2K in Q3 2024. 258 funds tracked by Wall St. Rank hold LGND as of Q4 2024.

  • Claris Advisors reported no remaining Ligand Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Claris Advisors sold 32 Ligand Pharmaceuticals shares in Q4 2024, an estimated $3.2K.
  • Claris Advisors first reported a position in Ligand Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Claris Advisors's Ligand Pharmaceuticals position peaked at $3.2K in Q3 2024.
  • 258 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2024.

Based on Claris Advisors's 13F filing for Q4 2024, filed 7 Feb 2025.